Fulcrum Therapeutics
Tracked across 2 events · 12 articles · First seen May 12, 2026 · Last active Jun 04, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Fulcrum Therapeutics, a publicly traded company, experienced a 50% stock plunge on June 1, 2026, after disclosing United States — Food and Drug Administration safety concerns related to the PRC2 inhibitor drug class, specifically regarding…
Impact: Fulcrum Therapeutics stock plunged 50% due to FDA safety concerns regarding its lead drug candidate, pociredir, leading to its discontinuation and a strategic review. The company is now under investigation for potential securities fraud.
Jun 02, 2026 · 6 articles
100
Fulcrum Therapeutics disclosed safety concernsFulcrum Therapeutics stock...
95
Fulcrum Therapeutics discontinued drug programFulcrum Therapeutics stock...
90
Levi & Korsinsky initiated investigation Fulcrum TherapeuticsFulcrum Therapeutics stock...
85
Fulcrum Therapeutics launched strategic reviewFulcrum Therapeutics stock...
70
Fulcrum Therapeutics made statementsFulcrum Therapeutics stock...
NEWSDESK
Track Fulcrum Therapeutics live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard